Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 6Phase 1 5Phase NA 1Phase 3 1Phase 2/3 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 384Carcinoma, Non-Small-Cell Lung 242Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 191Neoplasms 178Colorectal Neoplasms 160Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 126Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 113Squamous Cell Carcinoma of Head and Neck 106Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 87Carcinoma, Hepatocellular 79Triple Negative Breast Neoplasms 75Esophageal Neoplasms 75Endometrial Neoplasms 74Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 54Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

enzalutamide 1dactolisib 1NVP-BKM120 1Injections 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Castration-resistant Prostate Cancer × Genitourinary × Clear all
NCT06636123 2026-01-27

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Virginia Commonwealth University

Phase 1 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06343038 2024-08-14

PROGNOSTICS

University Hospital, Basel, Switzerland

Phase 1 Recruiting
25 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03136640 2021-10-19

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Modra Pharmaceuticals

Phase 1 Completed
23 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡